Immediate Impact
44 standout
Citing Papers
Deep Learning in Breast Cancer Imaging: A Decade of Progress and Future Directions
2024 Standout
HER2-targeted therapies in cancer: a systematic review
2024 Standout
Works of S Kirk being referenced
Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer
2017
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
2017
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| S Kirk | 81 | 215 | 97 | 131 | 11 | 321 | |
| H Tobon | 108 | 77 | 63 | 147 | 15 | 367 | |
| Suryanarayan V.S. Deo | 36 | 250 | 176 | 69 | 14 | 352 | |
| E Erbstösser | 48 | 163 | 114 | 173 | 8 | 364 | |
| F. Sciarretta | 93 | 149 | 50 | 58 | 17 | 312 | |
| R V Smalley | 30 | 193 | 53 | 82 | 13 | 321 | |
| I D H Todd | 62 | 133 | 63 | 38 | 10 | 309 | |
| Birthe Heitkötter | 42 | 98 | 170 | 28 | 18 | 311 | |
| V Eusebi | 62 | 117 | 71 | 184 | 8 | 368 | |
| J.C. Eymard | 85 | 141 | 230 | 100 | 20 | 335 | |
| Xiu-Yu Cai | 73 | 192 | 68 | 54 | 9 | 296 |
All Works
Loading papers...